Estimating scenarios for survival time in patients with advanced melanoma receiving immunotherapy and targeted therapy.

Simple multiples of the median OS are a useful framework to estimate scenarios for survival for patients receiving targeted therapies, not immunotherapy. Longer follow-up is required to estimate upper-typical and best-case scenarios.